Novo Hiring New Reps, Now They Need Something To Sell

Feb 6 2014, 1:43pm CST | by

Novo Hiring New Reps, Now They Need Something To Sell

In news that should come as a surprise to no one, it looks like Roche Diabetes Care is about to undergo yet another restructuring, which is really a nice way of saying more layoffs are coming. Perhaps the real news here is that Roche actually has anyone left in the unit to layoff. Like everyone else in conventional blood glucose monitoring, Roche has cut costs to the bone as they desperately try and find a buyer for this beleaguered unit.

Compare this news to an article that appeared in Fierce PharmaMarketing which stated:

“When we hear about companies actually hiring reps, that’s news. Given the thousands of sales layoffs over the past several years–and recruiting focused on emerging markets, especially China–staffing up in the U.S. or Europe is out of the ordinary. When that hiring isn’t about a new drug launch, we hardly know what to make of it.

That’s just what Novo Nordisk has been doing: hiring reps by the hundred in the U.S. First, it was in anticipation of the Tresiba launch that didn’t happen in 2013, but last fall, another 350 joined the company. Couple that with 120 new nurse educators, and the Danish drugmaker has expanded its field force by almost 15%.”

Granted the diabetes drug market is not as bad as the diabetes device market, but it won’t be long before it suffers the same fate, which makes this decision by Novo Nordisk (NVO) even stranger and not just from a cost perspective. It’s a well-known fact that the fewer and fewer physicians are actually seeing sales reps. It’s also true that while the physician would like to have control over which drugs they prescribe increasingly this decision is being taken away from the physician and put in the hands of the patients insurance company.

Although pharma reps hate to hear this, the reality is their job function can be easily and more cost effectively performed by an automated or virtual system. This is increasingly true with diabetes drugs which are filled with me-too copycats that all do basically the same thing pretty much the same way. The days of pharma reps sitting with physicians reviewing the latest study data are over, the simple fact is if a physician wants information on any drug the fastest, easiest way to get it is to surf the net. Add in the fact that either by law or by cost concerns also over are the days when reps can leave behind drug samples.

Novo’s decision to continue to add reps while the competition is moving in the exact opposite direction would make sense if they actually had something new to sell. Yet with Tresiba delayed at the FDA indefinitely we can’t quite figure out what exactly these people will be doing. This is not like the old days when a company could put an army of reps into the field and see an almost impact on sales growth. Novo already has a well-established and well known product line. So again just what new stories can these reps, the lucky few who actually get to sit down with a physician, say.

Lastly there is the cost issue which is a major issue when one considers that pricing pressure continues to intensify. This move to add reps makes me believe that old habits die hard at Novo as they continue to believe that they will receive premium pricing for the products they make. There continued pursuit to have Tresiba approved in the U.S. is another example of this.

While the FDA is being overly cautious with Tresiba, the fact is even if the drug does eventually make it to market it will have a tough time given it’s likely a generic version of Lantus will be available which will drive prices even lower.

Years ago I warned everyone that the BGM market was transforming itself from a medical device to commodity market where price trumps performance. Unfortunately for BGM companies this prediction came true and as a result they are watching a once prosperous business sink into oblivion. Unable to divest themselves of these units it makes perfect sense they would cut costs to the bone and get whatever they can from these units.

Today we’ve been warning everyone that the diabetes drug market is following this same path and every indicator tells us that this prediction is also coming true. The real question is can a company like Novo avoid the mistakes made by their BGM counterparts.

Can they, unlike their counterparts, adapt to this new environment, see realistically where this market is and more importantly where it is headed?  Their continued pursuit of Tresiba with the FDA and hiring even more reps tells Diabetic Investor that history will be repeating itself. That it won’t be long before that Novo also decides that it’s time to restructure and align costs with the new realities of this market.

We realize this not welcome news to all these new reps but it is unfortunately the way it is.

Source: Forbes Business

 
 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

Odyne Systems, LLC Partners with Allison Transmission’s Midwest Distributor, Inland Power, to Deliver on $45.4 Million Contract
Odyne Systems, LLC Partners with Allison Transmission’s Midwest Distributor, Inland Power, to Deliver on $45.4 Million Contract
Department of Energy Program Administered Through the Electric Power Research Institute to Apply Over 120 Odyne Plug-In Hybrid Systems to Trucks Throughout North America
 
 
Cleared Of Fraud Against SMEs, RBS Eases Rules For Distressed Businesses
Last week, The Royal Bank of Scotland Group was cleared by law firm Clifford Chance over allegations that the U.K.-based banking group deliberately put failing small and medium enterprise customers out of business to...
 
 
Cost Savings Are Allowing Colgate To Invest Back In Building Brands And Products
In the past several quarters, balancing the business mix between developed and emerging markets has helped Colgate-Palmolive to achieve above market growth and experience only a moderate impact on net sales from...
 
 
Shift In Agricultural Sales Timing, Lower Chemical Prices Weigh On DuPont's Earnings Growth
DuPont reported modest earnings growth for the first quarter due to lower agricultural sales volume and continuing pricing pressures in the chemicals segment. The company’s adjusted diluted earnings per share of $1.58...
 
 
 

Latest from the Network

Apple's Sales Figures Prove A Sad Fact: There's Still No PC As Desirable As A Mac
Mac sales make up just a tenth of Apple's revenue, but they’ve received a significant amount of attention following the company’s quarterly report yesterday, both from analysts and from the CEO Tim Cook himself. Cook’s...
Read more on Apple Balla
 
Apple's Analysts Almost Universally Positive On The March Quarter Results
Apple’s shares are up over $40 today driven by its very solid March quarter results and better than expected guidance for the June quarter. I have summarized over a dozen sell-side notes below and many analysts have...
Read more on Apple Balla
 
Odyne Systems, LLC Partners with Allison Transmission’s Midwest Distributor, Inland Power, to Deliver on $45.4 Million Contract
Waukesha, WI, April 24, 2014 --(PR.com)-- Odyne Systems of Waukesha and Inland Power Group of Butler, Wisconsin have teamed up to deliver on a $45.4 million contract from the Department of Energy, administered through...
Read more on Politics Balla
 
Odyne Systems, LLC Partners with Allison Transmission’s Midwest Distributor, Inland Power, to Deliver on $45.4 Million Contract
Waukesha, WI, April 24, 2014 --(PR.com)-- Odyne Systems of Waukesha and Inland Power Group of Butler, Wisconsin have teamed up to deliver on a $45.4 million contract from the Department of Energy, administered through...
Read more on Business Balla
 
Cleared Of Fraud Against SMEs, RBS Eases Rules For Distressed Businesses
Last week, The Royal Bank of Scotland Group was cleared by law firm Clifford Chance over allegations that the U.K.-based banking group deliberately put failing small and medium enterprise customers out of business to...
Read more on Business Balla
 
Cost Savings Are Allowing Colgate To Invest Back In Building Brands And Products
In the past several quarters, balancing the business mix between developed and emerging markets has helped Colgate-Palmolive to achieve above market growth and experience only a moderate impact on net sales from...
Read more on Business Balla
 
Shift In Agricultural Sales Timing, Lower Chemical Prices Weigh On DuPont's Earnings Growth
DuPont reported modest earnings growth for the first quarter due to lower agricultural sales volume and continuing pricing pressures in the chemicals segment. The company’s adjusted diluted earnings per share of $1.58...
Read more on Business Balla
 
Google's Glass Explorer Program Was A Social Experiment That Backfired
Google Glass was launched without any clear explanation of what it was supposed to be used for. When promotional videos started to show people going about their daily routine, it quickly became clear that what we were...
Read more on Business Balla
 
America's 100 Best Corporate Citizens in 2014
America’s 10 Best Corporate Citizens In 2014 In December Bristol-Myers Squibb joined the Medicines Patent Pool, an international organization in Geneva, Switzerland, that makes drugs available at low cost to people...
Read more on Business Balla
 
Talent Knows No Limits
Last month I had the pleasure of attending Cirque Du Soleil’s Michael Jackson tribute The Immortal World Tour. To say the performance was out of this world would be an understatement. If you’ve ever seen a Cirque show...
Read more on Business Balla
 
 
Auto Balla Sexy Balla Sport Balla TV Balla Politics Balla Movie Balla Apple Balla Business Balla Ad Balla Celebrity Balla